Eckert & Ziegler stock: NuWays rates Eckert & Ziegler stock Buy with EUR 21.50 target

Published on 10/19/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was EUR 149.30 million in first-half 2026. Eckert & Ziegler stock costs EUR 12.80 on October 19, 2026, 0.39 percent above Xetra close.

Analyst target and price position

On October 13, 2026, NuWays assigned Eckert & Ziegler a Buy rating and a EUR 21.50 target.
First-half 2026 revenue reached EUR 149.30 million versus EUR 148.80 million in the prior-year period.
Eckert & Ziegler stock costs EUR 12.80 at Lang & Schwarz on October 19, 2026 at 5:10 p.m. CEST, 0.39 percent above the Xetra close of October 16, 2026.
The company had a P/E ratio of 16.15 and a market capitalization of EUR 798.5 million on October 19, 2026.

CGI-Render eines modernen Unternehmensgebäudes mit Glasfassade bei Sonnenuntergang — Eckert & Ziegler DE0005659700 Medizintechnik: Architektur-Render eines modernen Firmengebäudes mit Glas-Stahl-Fassade bei Abenddämmerung in Berlin, Illustration mit AI erstellt.

NuWays rated Eckert & Ziegler stock Buy and set a EUR 21.50 12-month target in research dated October 13, 2026. The target stands 67.97 percent above the Lang & Schwarz price of EUR 12.80, calculated in euros. Eckert & Ziegler stock was trading at EUR 12.80 at Lang & Schwarz on October 19, 2026 at 5:10 p.m. CEST, up 0.39 percent versus the Xetra close of October 16, 2026 at EUR 12.75.

Revenue held nearly steady

First-half 2026 revenue reached EUR 149.30 million, compared with EUR 148.80 million in the prior-year period. Adjusted EBIT fell to EUR 33.30 million from EUR 35.40 million, while net income rose to EUR 22.40 million from EUR 21.40 million, according to 4investors on August 13, 2026. The company confirmed 2026 revenue guidance of EUR 320.00 million and adjusted EBIT guidance of EUR 80.00 million.

Stock sits below its yearly high

The intraday range on October 19, 2026 was EUR 12.68 to EUR 12.99, with a volume of 61,969 shares against an average volume of 112,674. The current price is 27.81 percent below the 52-week high of EUR 17.73 and 7.48 percent above the 52-week low of EUR 11.91.

Target leaves valuation gap

NuWays cited a 12-month target of EUR 21.50 and identified the stock's independent isotope supply and manufacturing position as key valuation factors in its October 13, 2026 research, published by TradingView. The P/E ratio was 16.15 and market capitalization was EUR 798.5 million on October 19, 2026.

Comparison with peers

Eckert & Ziegler: plus 0.39 percent, P/E 16.15, market capitalization EUR 798.5 million
Siemens Healthineers (Xetra, EUR): minus 1.42 percent, P/E 20.62, market capitalization EUR 45.7 billion
Telix Pharmaceuticals (ASX, USD): plus 1.14 percent, P/E 120.12, market capitalization USD 3.6 billion

Price remains the daily frame

The current quotation places Eckert & Ziegler below its 52-week high while the NuWays target remains materially above the market price. The company's first-half revenue was broadly stable, but adjusted EBIT was lower than in the prior-year period.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.